The COVID-19 pandemic has emerged as a serious global threat causing a large number
of fatalities and putting enormous strain on the health care resources across the world. This has resulted
in preferentially triaging the coronavirus infected patients and placing others, especially cardiovascular
patients at increased risk for adverse complications. The effective management of cardiac
patients in the hospital environment during this COVID-19 pandemic has emerged as a real
challenge. We try to address this issue and also highlight the interplay between COVID-19 and cardiovascular
diseases. We hereby review the available literature and emerging guidelines about cardiovascular
implications related to COVID-19 which will have a bearing on the patient care, health
care professionals and cardiac centres.
Keywords: COVID-19, cardiovascular, myocarditis, acute coronary syndrome, primary PCI, anxiety.
Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc 2007.
KALETRA. (R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution Product Insert AbbVie Inc (per FDA). IL: North Chicago 2013.
Prescribing information; Brilinta (ticagrelor). Wilmington, DE: AstraZeneca LP 2011.07.
Product monographBrilinta (ticagrelor). Mississauga, Ontario, Canada: AstraZeneca Canada Inc. 2011.
Rights & PermissionsPrintExport